B+
Bull case
25%
Probability
Target price
$3.60
Analysis reference price unavailable
Analysis 2026-10-29 · RankAlpha Sentiment Codex
CGEN
CompugenANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
A clear COM701 progression-free-survival benefit, supported by the reported $125.3 million June 2026 cash balance and runway expected into 2029, could materially improve the development outlook. [#PR-2026-08-03] Compugen results release
Posture
Constructive
Lead driver
Sentiment
What changed
Next scheduled catalyst: earnings 2026-11-09 · BMO.
What can break
AstraZeneca's early rilvegostomig data require randomized Phase 3 validation; no dated readout or CGEN payment forecast was confirmed. [#PR-2026-08-03] Compugen results release
Momentum
89
Value
56
Sentiment
69
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $2.15 · Bull $3.60 · Bear $0.90Analysis 2026-10-29; returns require an exact persisted reference.
Earnings
2026-11-09 · BMO
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-11-02 • Vendor: Data Vendor v1
Scores
As of 2026-11-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-29 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-11-02
Investment thesis
As of 2026-11-02
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-11-02. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $4.60
Why
Momentum89 · Δ7d -
Value56 · Δ7d -0.0
Sentiment69 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Next scheduled catalyst: earnings 2026-11-09 · BMO.
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • AstraZeneca's early rilvegostomig data require randomized Phase 3 validation; no dated readout or CGEN payment forecast was confirmed. [#PR-2026-08-03] Compugen results release
- • COM701 interim data could be delayed, inconclusive, or clinically disappointing.
- • The trial may produce weak or inconclusive data, while partner-program value is distant and its retained economics cannot be quantified from the supplied relationship observation.
Catalyst clock
2026-11-09 · BMO
COM701 MAIA-ovarian interim analysis
Lead driver: Sentiment · See AI snapshot
Momentum
89
18% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
56
43% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.2
Sentiment
69
39% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 89.1 / Value 55.9 / Sentiment 68.8
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-29. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$2.15
Analysis reference price unavailable
Analysis 2026-10-29 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$0.90
Analysis reference price unavailable
Analysis 2026-10-29 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-11-02
Fundamentals (TTM)
As of 2026-11-02
Market Cap
$187.56M
Beta
1.61
Shares Out
94.73M
P/E (TTM) · Derived
5.2
P/S (TTM)
21.00
P/FCF (TTM)
2.93
Rev YoY
+107.0%
EPS YoY
-5.7%
Gross Margin
+86.9%
Op Margin
+40.9%
Net Debt
-$142.68M
Current Ratio
5.72
As of 2026-11-02 • Updated nightlySource: Internal modelMethods & Data